Effects of tobacco smoking and nicotine on cancer treatment

Pharmacotherapy

Volumn 32, Issue 10, 2012, Pages 920-931

  Petros, William P ^a,b   Younis, Islam R ^c   Ford, James N ^a   Weed, Scott A ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cancer; Nicotine; Pharmacokinetics; Tobacco

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2E1; DOCETAXEL; ERLOTINIB; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 2B7; IMATINIB; IRINOTECAN; NICOTINE; NICOTINIC RECEPTOR; OROSOMUCOID; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TEGAFUR; UNCLASSIFIED DRUG; UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR RELATED PROTEIN 1; UROKINASE RECEPTOR;

ANEMIA; APOPTOSIS; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COLON CANCER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LOCALIZATION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LARYNX CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SMOKING; SOFT TISSUE SARCOMA; SOLID TUMOR; TUMOR PROMOTION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; NEOPLASMS; NICOTINE; OROSOMUCOID; PROGNOSIS; SMOKING; TISSUE DISTRIBUTION;

EID: 84867299324     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01117     Document Type: Review

References (75)

1. U.S. Centers for Disease Control & Prevention. State-specific prevalence and trends in adult cigarette smoking - United States, 1998-2007. MMWR Morb Mortal Wkly Rep, 2009;58:221-6.
2. Garces YI, Yang P, Parkinson J, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest 2004;126:1733-41.
3. Burke L, Miller L-A, Saad A, Abraham J. Smoking behaviors among cancer survivors: an observational clinical study. J Oncol Pract 2009;5:6-9.
4. Gritz E, Fingeret MC, Vidrine DJ, et al. Successes and failures of the teachable moment - Smoking cessation in cancer patients. Cancer 2006;106:17-27.
5. Morgan G, Schnoll RA, Alfano CM, et al. National Cancer Institute Conference on Treating Tobacco Dependence at Cancer Centers. J Oncol Pract 2011;7:178-82.
6. Ebbert JO, Williams BA, Sun Z, et al. Duration of smoking abstinence as a predictor for non-small-cell lung cancer survival in women. Lung Cancer 2005;47:165-72.
7. Fortin A, Wang CS, Vigneault E. Influence of smoking and alcohol drinking behaviors on treatment outcomes of patients with squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2009;74:1062-9.
8. Petros WP, Evans WE. Anticancer agents. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied pharmacokinetics & pharmacodynamics - principles of therapeutic drug monitoring. Philadelphia, PA: Lippincott Williams & Wilkins, 2006:617-36.
9. Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362:2295-303.
10. Wells AJ, English PB, Posner SF, Wagenknecht LE, Perez-Stable EJ. Misclassification rates for current smokers misclassified as nonsmokers. Am J Public Health 1998;88:1503-9.
11. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001;33:161-235.
12. Lind P, Engström G, Stavenow L, Janzon L, Lindg rde F, Hedblad B. Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol 2004;24:577-82.
13. Moszczyński P, Zabiński Z, Moszczyński P Jr, Rutowski J, Słowiński S, Tabarowski Z. Immunological findings in cigarette smokers. Toxicol Lett 2001;118:121-7.
14. Tappia PS, Troughton KL, Langley-Evans SC, Grimble RF. Cigarette smoking influences cytokine production and antioxidant defenses. Clin Sci (Lond) 1995;88:485-9.
15. Shima M, Adachi M. Effects of environmental tobacco smoke on serum levels of acute phase proteins in schoolchildren. Prev Med 1996;25:617-24.
16. Uslu C, Taysi S, Ackay F, Sutbeyaz MY, Bakan N. Serum free and bound sialic acid and alpha-1-acid glycoprotein in patients with laryngeal cancer. Ann Clin Lab Sci 2003;33:156-9.
17. Duché J, Urien S, Simon N, Malaurie E, Monnet I, Barré J. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem 2000;33:197-202.
18. Budai L, Ozohanics O, Luda'nyi K, et al. Investigation of genetic variants of alpha-1 acid glycoprotein by ultra-performance liquid chromatography-mass spectrometry. Anal Bioanal Chem 2009;393:991-8.
19. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 2006;45:235-52.
20. Minami H, Kawada K, Sasaki Y, et al. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Sci 2006;97:235-41.
21. Bruno R, Viivier N, Vergniol JC, et al. A population pharmacokinetic model for docetaxel (Taxotere), model building and validation. J Pharmacokinet Biopharm 1996;24:153-72.
22. Baker SD, Li J, ten Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005;77:43-53.
23. Puisset F, Alexandre J, Treluyer J-M, et al. Clinical Pharmacodyanmic factors in docetaxel toxicity. Br J Cancer 2007;97:290-6.
24. von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 2011;37:291-9.
25. Delbaldo C, Chatelut E, Ré M, et al. Pharmacokinetic- pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006;12:6073-8.
26. Widmer N, Decosterd LA, Leyvraz S, et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 2008;98:1633-40.
27. van Erp N, Gelderblom H, van Glabbeke M, et al. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. Clin Cancer Res 2008;14:8308-13.
28. Kushinsky R, Louis CJ. The effect of cigarette smoke on aryl hydrocarbon hydroxylase activity and cytochrome P450 content in rat liver and lung microsomes. Oncology 1976;33:197- 200.
29. Vistisen K, Loft S, Poulsen HE. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. Adv Exp Med Biol 1991;283:407-11.
30. Anttila S, Tuominen P, Hirvonen A, et al. CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor. Pharmacogenetics 2001;11:501-9.
31. Smith GB, Harper PA, Wong JM, et al. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2001;10:839-53.
32. Shah PP, Saurabh K, Pant MC, et al. Evidence for increased cytochrome P450 1A1 expression in blood lymphocytes of lung cancer patients. Mutat Res 2009;670:74-8.
33. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42:268- 354.
34. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-88.
35. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178-84.
36. Bloom J, Hinrichs AL, Wang JC, et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics 2011;21:403-16.
37. Helmig S, Seelinger JU, Philipp-Gehlhaar M, et al. Cyp1B1 mRNA expression in correlation to cotinine levels with respect to the Cyp1B1 L432V gene polymorphism. Eur J Epidemiol 2010;25:867-73.
38. Port JL, Yamaguchi K, Du B, et al. Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis 2004;25:2275-81.
39. Thum T, Erpenbeck VJ, Moeller J, et al. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 2006;114:1655-61.
40. Schoedel KA, Sellers EM, Palmour R, Tyndale RF. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacol 2003;63:96-104.
41. Hukkanen J, Jacob Iii P, Peng M, et al. Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol 2010;69:152-9.
42. Seree EM, Villard PH, Re JL, et al. High inducibility of mouse renal CYPZE1 gene by tobacco smoke and its possible effect on DNA single strand breaks. Biochem Biophys Res Commun 1996;219:429-34.
43. Benowitz NL, Peng M, Jacob P 3rd. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther 2003;74:468-74.
44. Collier AC, Tingle MD, Paxton JW, et al. Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. Hum Reprod 2002;17:2564-72.
45. Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 2010;42:209-24.
46. Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12:2166- 71.
47. Lu JF, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006;80:136-45.
48. Hughes AN, O'Brien ME, Petty WJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009;27:1220-6. Epub 2009 Jan 21
49. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863-9.
50. Chuah B, Goh BC, Lee SC, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 2011;102:478-83.
51. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001;41:535-67.
52. van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007;25:2719-26.
53. Benowitz NL. Cigarette smoking and the personalization of irinotecan therapy. J Clin Oncol 2007;25:2646-7. Epub 2007 Jun 11.
54. Hect SS. Tobacco. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer - principles and practice of oncology. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins, 2011:150-60.
55. Catassi A, Servent D, Paleari L, Cesario A, Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res 2008;659:221-31. Epub 2008 Apr 11.
56. Carracedo DG, Rodrigo JP, Nieto CS, Gonzalez MV. Epithelial cell nicotinic acetylcholine receptor expression in head and neck squamous cell carcinoma pathogenesis. Anticancer Res 2007;27:835-9.
57. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 1990;87:3294-8.
58. Al-Wadei HA, Plummer HK 3rd, Schuller HM. Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid. Carcinogenesis 2009;30:506-11. Epub 2009 Jan 8.
59. Grando SA. Basic and clinical aspects of non-neuronal acetylcholine: biological and clinical significance of non-canonical ligands of epithelial nicotinic acetylcholine receptors. J Pharmacol Sci 2008;106:174-9. Epub 2008 Feb 16.
60. Jull BA, Plummer HK 3rd, Schuller HM. Nicotinic receptormediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol 2001;127:707-17.
61. Davis R, Rizwani W, Banerjee S, et al. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS ONE 2009;4:e7524.
62. Tsurutani J, Castillo SS, Brognard J, et al. Tobacco components stimulate Akt-dependent proliferation and NFkappaBdependent survival in lung cancer cells. Carcinogenesis 2005;26:1182-95. Epub 2005 Mar 24.
63. Dasgupta P, Rastogi S, Pillai S, et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006;116:2208-17.
64. Jin Z, Gao F, Flagg T, Deng X. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J Biol Chem 2004;279:23837-44. Epub 2004 Mar 22.
65. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci USA 2006;103:6332-7. Epub 2006 Apr 6.
66. Villablanca AC. Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro. J Appl Physiol 1998;84:2089-98.
67. Zhu BQ, Heeschen C, Sievers RE, et al. Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell 2003;4:191-6.
68. Singh S, Pillai S, Chellappan S. Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J Oncol 2011;2011:456743. Epub 2011 Mar 30.
69. Heeschen C, Chang E, Aicher A, Cooke JP. Endothelial progenitor cells participate in nicotine-mediated angiogenesis. J Am Coll Cardiol 2006;48:2553-60. Epub 2006 Nov 28.
70. Dasgupta P, Rizwani W, Pillai S, et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 2009;124:36-45.
71. Murin S, Inciardi J. Cigarette smoking and the risk of pulmonary metastasis from breast cancer. Chest 2001;119:1635-40.
72. Murin S, Pinkerton KE, Hubbard NE, Erickson K. The effect of cigarette smoke exposure on pulmonary metastatic disease in a murine model of metastatic breast cancer. Chest 2004;125:1467-71.
73. Lazar M, Sullivan J, Chipitsyna G, et al. Induction of monocyte chemoattractant protein-1 by nicotine in pancreatic ductal adenocarcinoma cells: role of osteopontin. Surgery 2010;148:298-309. Epub 2010 Jun 25.
74. Shields PG. Long-term nicotine replacement therapy: cancer risk in context. Cancer Prev Res 2011;4:1719-23.
75. Goldstein AO, Ripley-Moffitt CE, Pathman D, Patsakham KM. Tobacco use treatment at the U.S. National Cancer Institute's designated cancer centers. Nicotime Tobacco Res 2012; Apr 11 [e-pub ahead of print].